| 1141/1816 | US=69 / Câncer Quintás-Cardama A, Kantarjian H, Garcia-Manero G, Cortes J. Targeted therapy in myelodysplastic syndrome. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 237-60. ISBN 978-1-60327-423-4. TERAPIA-ALVO; SINDROME MIELODISPLASICA; DECITABINA; A METILACAO DO DNA; 5-AZACITIDINA; LENALIDOMIDA |
| 1142/1816 | US=69 / Câncer Markman M. Targeted therapy in epithelial ovarian cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 261-9. ISBN 978-1-60327-423-4. TERAPIA-ALVO; CANCER EPITELIAL DE OVARIO; CANCRO DO OVARIO; CISPLATINA; CARBOPLATINA; AGENTES ANTI-ANGIOGENICOS; BEVACIZUMAB |
| 1143/1816 | US=69 / Câncer Gibbons DL, Wolff RA, Varadhachary G. Targeted drug therapy in pancreatic cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 271-87. ISBN 978-1-60327-423-4. TERAPIA MEDICAMENTOSA ALVO DE CANCER DE PANCREAS; TERAPIA-ALVO; CANCER DE PANCREAS; QUIMIOTERAPIA; ENSAIOS CLINICOS |
| 1144/1816 | US=69 / Câncer Zurita AJ, Ward JF, Kim J. Targeted therapy in prostate cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 289-304. ISBN 978-1-60327-423-4. TERAPIA-ALVO; CANCER DE PROSTATA; CANCER DE PROSTATA; NEOPLASIA DE PROSTATA; RESISTENTE A CASTRACAO CANCRO DA PROSTATA; ANDROGENO RECEPTOS; ANSAMICINAS; MTOR; ANGIOGENESE; IMUNOTERAPIA |
| 1145/1816 | US=69 / Câncer Jonasch E, Tannir N. Targeted therapy in renal cell carcinoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 305-16. ISBN 978-1-60327-423-4. TERAPIA-ALVO; CARCINOMA DE CELULAS RENAIS; MUTACAO BVS; ANTIVASCULAR TERAPIA; TERAPEUTICA DE COMBINACAO; TERAPIA SEQUENCIAL |
| 1146/1816 | US=69 / Câncer Ludwing J, Trent JC. Targeted therapy of sarcoma. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 317-34. ISBN 978-1-60327-423-4. TERAPIA-ALVO DE SARCOMA; SARCOMA; MOLECULAR; ALVO; TERAPIA PERSONALIZADA |
| 1147/1816 | US=69 / Câncer Kundra V, Schellingerhout D, Jackson EF. Targeted and functional imaging. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 335-60. ISBN 978-1-60327-423-4. IMAGEM ALVO; IMAGEM FUNCIONAL; IMAGEM MOLECULAR; SPECT; PET; MR; DCE-MR |
| 1148/1816 | US=69 / Câncer Hong D, Chintala L. Combining targeted therapies. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 361-81. ISBN 978-1-60327-423-4. COMBINANDO TERAPIAS-ALVO; TERAPIA-ALVO; TERAPIA PERSONALIZADA; VIAS DE SINALIZACAO; RESISTENCIA A DROGAS; DESENVOLVIMENTO DE DROGAS |
| 1149/1816 | US=69 / Câncer Camacho LH. Drug development in cancer medicine: challenges for targeted approaches. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 383-410. ISBN 978-1-60327-423-4. DESENVOLVIMENTO DE DROGAS EM CANCER; TERAPIA-ALVO; DESAFIOS; OBSTACULOS; DESENVOLVIMENTO DE DROGAS; ENSAIOS CLINICOS; FASE I |
| 1150/1816 | US=69 / Câncer Welsh SJ, Powis G. Toward personalized therapy for cancer. In: Kurzrock R, Markman M. Targeted Cancer therapy. 2nd. New Jersey: Humana Press, 2008. p. 411-25. ISBN 978-1-60327-423-4. TERAPIA PERSONALIZADA PARA O CANCER; CANCER; MEDICINA PERSONALIZADA; TERAPIA INDIVIDUALIZADA; FARMACOGENOMICA; TERAPIA-ALVO; ALVOS MOLECULARES |
| 1151/1816 | US=58 / Câncer Dijkstra KK, Blanchetot C, Boonstra. Evasion of G1 checkpoints in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 3-26. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLE G1 EM CANCER; CICLO CELULAR; CHECKPOINT G1 CEDO; PONTO DE RESTRICAO; ESTRESSE MITOGENICA HIPER; CHECKPOINT ENERGIA; ROS |
| 1152/1816 | US=58 / Câncer Hurley PJ, Bunz F. Distinct pathways involved in s-phase checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 27-36. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLO S-CHECKPOINT; INTRA-S-FASE CHECKPOIN; CHECKPOIN REPLICACAO; S-M CHECKPOINT; ATR; CHK1; CHK2; REPLICACAO DO DNA |
| 1153/1816 | US=58 / Câncer Kuang J, Wang R. Mechanisms of G2 phase arrest in DNA damage-induced checkpoint response. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 37-51. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. G2 CHECKPOINT; CDC25; PP2A; 14-3-3; 14-3-3O; P53; P21; GADD45 |
| 1154/1816 | US=58 / Câncer Krämer A. Centrosomes in checkpoint responses. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 53-67. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CENTROSSOMAS NAS RESPOSTAS CHECKPOINT; CENTROSSOMA; DANOS NO DNA; CHECK-POINT; CHK1; PERICENTRIN; MICROCEFALINA; CDC25; SINDROME SECKEL; MICROCEFALIA; AMPLIFICACAO CENTROSSOMA; CATASTROFE MITOTICA |
| 1155/1816 | US=58 / Câncer Lee MH, Yeung SCJ, Yang HY. Interplay of 14-3-3 family of proteins with DNA damage-regulated molecules in checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 69-80. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FAMILIA DE PROTEINAS COM 14-3-3; DANOS AO DNA; RESPOSTA CHECKPOINT; 14-3-3; AKT; MDM2; P53; DANOS NO DNA |
| 1156/1816 | US=58 / Câncer Nakanishi M. Chromatin modifications and orchestration of checkpoint response in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 83-93. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. MODIFICACOES DE CROMATINA; ORQUESTRACAO DE RESPOSTA; CONTROLE EM CANCER; CHK1; CHK2; P53; REPLICACAO DO DNA |
| 1157/1816 | US=58 / Câncer Kaina B, Roos WP, Christmann M. DNA damage response and the balance between cell survival and cell death. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 95-108. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DANOS NO DNA; SOBREVIVENCIA CELULAR; MORTE CELULAR; CHECKPOINTS; CICLO CELULAR; RESPOSTA A DANOS DO DNA; REPARACAO DO ADN; P53; APOPTOSE; RECEPTORES DE MORTE; FAS; CAIXA ELETRONICO; ATR; DROGAS ANTICANCER |
| 1158/1816 | US=58 / Câncer Pentimalli F, Cito L, Giordano A. Dysfunction of the RB retinoblastoma gene in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 109-22. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. DISFUNCAO DO GENE; RETINOBLASTOMA RB NO CANCER; RETINOBLASTOMA; FAMILIA RB; SUPRESSORES TUMORAIS; CICLO CELULAR; G1-S DE TRANSICAO; CHECKPOINTS; E2F |
| 1159/1816 | US=58 / Câncer Alao JP. G1 phase cyclins in cancer development and progression. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 123-53. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. FASE G1; CICLINAS EM CANCER; CICLO CELULAR; FASE G1; CICLINA D1; CICLINA E; CANCER; ONCOGENE; UBIQUITINA; PROTEASSOMA 26S; TERAPIA DO CANCER |
| 1160/1816 | US=58 / Câncer Friedenson B. The BRCA1/2 pathway prevents some leukemias and lymphomas in addition to breast/ovarian cancers: malignancies that overcome checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 155-68. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. BRCA1; BRCA2; REPARACAO DO ADN; LEUCEMIAS; LINFOMAS; LINFOMA DE CELULAS DO MANTO; LEUCEMIA MIELOIDE AGUDA |